These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38419941)

  • 41. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
    Uemura Y; Kobayashi K
    Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
    Yu RZ; Graham MJ; Post N; Riney S; Zanardi T; Hall S; Burkey J; Shemesh CS; Prakash TP; Seth PP; Swayze EE; Geary RS; Wang Y; Henry S
    Mol Ther Nucleic Acids; 2016 May; 5(5):e317. PubMed ID: 27138177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
    Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
    J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense oligonucleotides and nucleic acids generate hypersensitive platelets.
    Zaslavsky A; Adams M; Cao X; Yamaguchi A; Henderson J; Busch-Østergren P; Udager A; Pitchiaya S; Tourdot B; Kasputis T; Church SJ; Lee SK; Ohl S; Patel S; Morgan TM; Alva A; Wakefield TW; Reichert Z; Holinstat M; Palapattu GS
    Thromb Res; 2021 Apr; 200():64-71. PubMed ID: 33540294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
    Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
    Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug Discovery Perspectives of Antisense Oligonucleotides.
    Kim Y
    Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.
    Weidolf L; Björkbom A; Dahlén A; Elebring M; Gennemark P; Hölttä M; Janzén D; Li X; Andersson S
    Drug Discov Today; 2021 Oct; 26(10):2244-2258. PubMed ID: 33862193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydrophobicity Tuning of Cationic Polyaspartamide Derivatives for Enhanced Antisense Oligonucleotide Delivery.
    Yum J; Aulia F; Kamiya K; Hori M; Qiao N; Kim BS; Naito M; Ogura S; Nagata T; Yokota T; Uchida S; Obika S; Kim HJ; Miyata K
    Bioconjug Chem; 2024 Feb; 35(2):125-131. PubMed ID: 38290165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides.
    Dieckmann A; Hagedorn PH; Burki Y; Brügmann C; Berrera M; Ebeling M; Singer T; Schuler F
    Mol Ther Nucleic Acids; 2018 Mar; 10():45-54. PubMed ID: 29499955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
    Laxton C; Brady K; Moschos S; Turnpenny P; Rawal J; Pryde DC; Sidders B; Corbau R; Pickford C; Murray EJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3105-14. PubMed ID: 21502629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.
    Nishina T; Numata J; Nishina K; Yoshida-Tanaka K; Nitta K; Piao W; Iwata R; Ito S; Kuwahara H; Wada T; Mizusawa H; Yokota T
    Mol Ther Nucleic Acids; 2015 Jan; 4(1):e220. PubMed ID: 25584900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A single-cell map of antisense oligonucleotide activity in the brain.
    Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
    Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry.
    Murray S; Ittig D; Koller E; Berdeja A; Chappell A; Prakash TP; Norrbom M; Swayze EE; Leumann CJ; Seth PP
    Nucleic Acids Res; 2012 Jul; 40(13):6135-43. PubMed ID: 22467214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.
    Subramanian RR; Wysk MA; Ogilvie KM; Bhat A; Kuang B; Rockel TD; Weber M; Uhlmann E; Krieg AM
    Nucleic Acids Res; 2015 Oct; 43(19):9123-32. PubMed ID: 26446989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of Locked Nucleic Acid Gapmers from Mouse Muscle Samples Using ELISA.
    Lim KRQ; Nguyen Q; Yokota T
    Methods Mol Biol; 2020; 2176():233-239. PubMed ID: 32865795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
    Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
    Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.